MITF-M dimer binds the MET promoter

Stable Identifier
R-HSA-9825836
Type
Reaction [binding]
Species
Homo sapiens
Compartment
nucleoplasm
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
MITF-M dimer binds the MET promoter
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
The hepatocyte growth factor (HGF) receptor MET is a direct transcriptional target of MITF. Stimulation of the cAMP pathway in human primary melanocytes and human and mouse melanoma cell lines with alpha-MSH or forskolin treatment causes upregulation of MET mRNA and protein levels. Upregulation depends on MITF and a conserved E-box at position -83 to -89 (numbering from mouse, equivalent to -109 in human) in the promoter, as assessed by reporter gene assay (Beuret et al, 2007). Two other studies examining the response of melanocytes and melanoma cells to stimulation by the MET ligand HGF similarly identified MET as a direct transcriptional target of MITF through ChIP and EMSA, however these studies identified the critical promoter E-box at position -300 (human numbering) (McGill et al, 2006; Mascarenhas et al, 2010). This site was not identified for response to alpha-MSH or forskolin in the Beuret study.
In normal melanocytes, MET signaling contributes to survival, proliferation and differentiation of melanocyte precursors, while in melanoma, MET expression is associated with disease progression and metastasis (Kos et al, 1999; Kunisada et al, 2000; Natali et al, 1993; Puri et al, 2007; Saitoh et al, 1994; reviewed in Cheli et al, 2010; Goding and Arnheiter, 2019; Gentile et al, 2008).
Literature References
PubMed ID Title Journal Year
8104462 Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression

Comoglio, PM, Nicotra, MR, Prat, M, Bigotti, A, Natali, PG, Cavaliere, R, Di Renzo, MF

Br J Cancer 1993
20067553 PAX3 and SOX10 activate MET receptor expression in melanoma

Littlejohn, EL, Salgia, R, Lang, D, Mascarenhas, JB, Young, KP, Wolsky, RJ, Nelson, M

Pigment Cell Melanoma Res 2010
17404109 c-Met is a potentially new therapeutic target for treatment of human melanoma

Tretiakova, M, Jagadeeswaran, R, Ahmed, S, Krausz, T, Salgia, R, Zumba, O, Janamanchi, V, Puri, N

Clin Cancer Res 2007
17371876 Up-regulation of MET expression by alpha-melanocyte-stimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis

Bertolotto, C, Picardo, M, Bille, K, Denoyelle, C, Beuret, L, Busca, R, Flori, E, Ballotti, R

J Biol Chem 2007
16455654 c-Met expression is regulated by Mitf in the melanocyte lineage

McGill, GG, Nishimura, EK, Haq, R, Fisher, DE

J Biol Chem 2006
19995375 Fifteen-year quest for microphthalmia-associated transcription factor target genes

Bertolotto, C, Cheli, Y, Ohanna, M, Ballotti, R

Pigment Cell Melanoma Res 2010
18175071 The Met tyrosine kinase receptor in development and cancer

Comoglio, PM, Gentile, A, Trusolino, L

Cancer Metastasis Rev 2008
31123060 MITF-the first 25 years

Arnheiter, H, Goding, CR

Genes Dev 2019
10842060 Keratinocyte expression of transgenic hepatocyte growth factor affects melanocyte development, leading to dermal melanocytosis

Hayashi, SI, Koshimizu, U, Kamei, S, Nakamura, T, Hemmi, H, Tagaya, H, Yamazaki, H, Omoteno, M, Kunisada, T, Hirobe, T

Mech Dev 2000
10193678 Hepatocyte growth factor/scatter factor-MET signaling in neural crest-derived melanocyte development

Kos, L, Ponzetto, C, Takayama, H, Merlino, G, Aronzon, A, Maina, F, Pavan, W

Pigment Cell Res 1999
7823252 Detection of the c-met proto-oncogene product in normal skin and tumours of melanocytic origin

Sawada, N, Takahashi, H, Parsons, PG, Saitoh, K

J Pathol 1994
Participants
Input
Output
Participates
as an event of
Authored
Rothfels, K  (2023-01-26)
Reviewed
de la Serna, IL  (2024-05-21)
Arnheiter, H  (2024-02-26)
Steingrímsson, E  (2024-11-05)
Vu, HN  (2024-11-05)
Created
Rothfels, K  (2023-01-27)
Cite Us!